Crossmark

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

Crossref DOI link: https://doi.org/10.1186/s12885-016-2656-8

Published Online: 2016-08-11

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nile, Donna L.

Rae, Colin

Hyndman, Iain J.

Gaze, Mark N.

Mairs, Robert J.
Funding

Funding for this research was provided by:

CHILDREN with CANCER UK (W1057)

Prostate Cancer UK (PG12-12)

Action Medical Research

Neuroblastoma Society
License Information

License valid from 2016-08-11